-
Clinicohematologic and Molecular Response of Essential Thrombocythemia Patients Treated with Pegylated Interferon-Alpha: A Multicenter Study on Behalf of the German Study Group-MPN (GSG-MPN)
Frank Stegelmann, Lino Lars Teichmann, Florian Heinrich Heidel, Carl C. Crodel, Thomas Ernst, Sebastian Kreil, +11 more
0citations -
Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis
Julia Marie Unglaub, Richard F. Schlenk, Maher Hanoun, Hans Christian Reinhardt, Jan Moritz Middeke, Kerstin Schäfer‐Eckart, +30 more
0citations -
Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All-Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)
Inga Hund, Maria Elena Hess, Julia Stomper, Gabriele Greve, Jan Mitschke, Christoph Niemöller, +13 more
0citations -
Eltrombopag plus cyclosporine A for moderate aplastic anemia (EMAA): a placebo-controlled, double-blind, phase 3 trial2026 Blood article Biochemistry, Genetics and Molecular Biology Blood disorders and treatments Open access
Britta Höchsmann, Philippe Schafhausen, Fabian Beier, Michael Heuser, Jörg Westermann, Beatrice Drexler, +13 more
0citations -
Does a Change in IPSS-R between Diagnosis and Transplant Have an Impact on Transplant Outcome in Patients with MDS? a Retrospective Analysis from the EBMT Chronic Malignancies Working Party
Christof Scheid, Dirk‐Jan Eikema, Riitta Niittyvuopio, Johan A. Maertens, Jakob Robert Passweg, Didier Blaise, +18 more
0citations